CoChat
Sign Up
Cited by 358Pharmacology and Obesity TreatmentBariatric Surgery and OutcomesDiabetes Treatment and Management

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

Heymsfield, Steven B., Segal, Karen R., Hauptman, Jonathan, Lucas, Charles P., Boldrin, Mark N., Rissanen, Aila, Wilding, John P. H., Sjöström, Lars·2000·Archives of Internal Medicine
DOI 10.1001/archinte.160.9.1321
Open this paper in CoChat — free account

Abstract

BACKGROUND: Orlistat is a gastrointestinal lipase inhibitor that reduces dietary fat absorption by approximately 30%, promotes weight loss, and may reduce the risk of developing impaired glucose tolerance and type 2 diabetes in obese subjects. OBJECTIVE: To test the hypothesis that orlistat combined with dietary intervention improves glucose tolerance status and prevents worsening of diabetes status more effectively than placebo. METHODS: We pooled data from 675 obese (body mass index, 30-43 kg/m2) adults at 39 US and European research centers in 3 randomized, double-blind, placebo-controlled multicenter clinical trials. Subjects received placebo plus a low-energy diet during a 4-week lead-in period. On study day 1, the diet was continued, and subjects were randomized to receive placebo 3 times a day (n=316) or treatment with orlistat, 120 mg 3 times a day (n=359), for 104 weeks. A standard 3-hour oral glucose tolerance test was performed on day 1 and at the end of treatment. MAIN OUTCOME MEASURES: The categorical assessment of glucose tolerance status (normal, impaired, diabetic) and changes in status from randomization to end of treatment were the primary efficacy measures. The secondary measures were fasting and postchallenge glucose and insulin levels. RESULTS: The mean length of follow-up was 582 days. Subjects who were treated with orlistat lost more weight (mean +/- SEM, 6.72 +/- 0.41 kg from initial weight) than subjects who received placebo (3.79+/-0.38 kg; P<.001). A smaller percentage of subjects with impaired glucose tolerance at baseline progressed to diabetic status in the orlistat (3.0%) vs placebo (7.6%) group. Conversely, among subjects with impaired glucose tolerance at baseline, glucose levels normalized in more subjects after orlistat treatment (71.6%) vs placebo (49.1%; P=.04). CONCLUSIONS: The addition of orlistat to a conventional weight loss regimen significantly improved oral glucose tolerance and diminished the rate of progression to the development of impaired glucose tolerance and type 2 diabetes.

Integrity signals

Registry

Crossref · 10.1001/archinte.160.9.1321

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a post hoc analysis of obese people, orlistat was associated with greater weight loss (6.7 vs 3.8 kg) compared to placebo and a significantly reduced conversion from IGT to diabetes (7.6% vs 3.0%) in a 1.5-year follow-up.

    “In a post hoc analysis of obese people, this drug was associated with greater weight loss (6.7 vs. 3.8 kg) compared to placebo with a significantly reduced conversion from IGT to diabetes (7.6% vs. 3.0%) in a 1.5-year follow-up.109”

    From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [109]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Heymsfield, S. B., Segal, K. R., Hauptman, J., Lucas, C. P., Boldrin, M. N., Rissanen, A., Wilding, J. P. H., & Sjöström, L.
Affiliations
St. Luke's-Roosevelt Hospital Center (US)
Corresponding author
Heymsfield, Steven B.
ORCID
Venue
Archives of Internal Medicine
Publisher
American Medical Association (AMA)
Published
2000-05-08
Volume
160
Issue
9
Pages
1321
ISSN
0003-9926 (ISSN-L)
DOI
10.1001/archinte.160.9.1321
OpenAlex
W1970652218
Cited by
358
References
22
Citations by year
2026: 1 · 2025: 3 · 2024: 6 · 2023: 11 · 2022: 9 · 2021: 5 · 2020: 4 · 2019: 9 · 2018: 8 · 2017: 5 · 2016: 8 · 2015: 7 · 2014: 10 · 2013: 11 · 2012: 12
FWCI
18.11
Type
journal article
Language
en
Open access
closed
Locations
  • Archives of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
orlistat, weight loss, obesity, type 2 diabetes prevention, impaired glucose tolerance, glucose tolerance, lipase inhibitors, dietary fat absorption, hypocaloric diet, insulin, fasting blood glucose
MeSH terms
Orlistat, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Insulin, Lactones, Lipase, Male, Middle Aged, Weight Loss, Disease Progression, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review